Fitbit (Charge / Sense / Versa)

Fitbit, founded in 2007 by James Park and Eric Friedman and acquired by Google in a roughly $2.1 billion deal that closed in January 2021, is now a Google product line rather than an independent company, and its devices are biometric-primary fitness bands and watches with atrial-fibrillation AI augmentation. Its current and last-generation devices include the Charge 6 from 2023, the Sense 2, and the Versa 4, carrying optical heart-rate sensing, ECG electrodes on the Sense line, a continuous electrodermal stress sensor on the Sense 2, blood oxygen, and skin temperature, plus Sleep Score, Sleep Profile, a Daily Readiness Score, and stress management. Its FDA clearances are the ECG app, cleared in September 2020 for on-demand assessment of atrial fibrillation versus sinus rhythm, and passive PPG-based Irregular Heart Rhythm Notifications, cleared on April 11, 2022 across a broad device range. Its blood oxygen, electrodermal stress, Sleep Score, and Daily Readiness features are wellness-grade and not FDA-cleared for any diagnostic claim. On current state, while standalone Fitbit-branded smartwatch hardware has been deprioritized with no Sense 3 and the smartwatch strategy consolidated onto the Pixel Watch, Google confirmed in October 2025 that new Fitbit hardware, expected to be trackers, is coming in 2026 along with a Fitbit Coach AI feature, so the line is deprioritized rather than dead. Its clinical-validation posture is the strongest in the cohort specifically on atrial fibrillation, anchored by the large prospective Fitbit Heart Study, while the 2026 Fitbit hardware specifications and the Fitbit Coach AI capabilities are unannounced and not verified.

Fitbit (Charge / Sense / Versa) is listed at $110 on the DEPLOY registry. This is an actual sale price on record.

Yes. Fitbit (Charge / Sense / Versa) is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Partly. DEPLOY verifies Fitbit (Charge / Sense / Versa) operating autonomously for Tracks sleep and Tracks fitness and activity. Other capabilities (Tracks heart health) are only demonstrated under teleoperation or remain vendor claims, not independently verified as autonomous.

Fitbit (Charge / Sense / Versa)'s recorded specifications on the DEPLOY registry: Battery: 7 days; Weight: 0.005 kg. See the Specs section for the full sourced set.

Fitbit (Charge / Sense / Versa) is made by Fitbit, based in San Francisco, California, USA, founded in 2007.

1 verified deployment of Fitbit (Charge / Sense / Versa) is on the DEPLOY registry, including at Global.

Fitbit (Charge / Sense / Versa) is available for purchase - a real sale price is on record (see the pricing section for the figure and its source).

Fitbit (Charge / Sense / Versa) has 4 regulatory records on the DEPLOY registry: FDA 510(k) clearance (K212372), cleared; FDA 510(k) clearance (K212372), cleared; FDA 510(k) clearance (K200948), cleared and 1 more. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable biometric robots to Fitbit (Charge / Sense / Versa) include Blackrock Neuroport Array, BrainQ Non-Invasive BCI, Neko Body Scan, RNS System.

Fitbit (Charge / Sense / Versa) and Blackrock Neuroport Array (Blackrock Neurotech · 5 deployments) are both biometric robots on the DEPLOY registry. Fitbit (Charge / Sense / Versa) has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Fitbit (Charge / Sense / Versa) ranks in roughly the top 59% of biometric models tracked by the registry.

Fitbit (Charge / Sense / Versa) is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Fitbit (Charge / Sense / Versa) has 1 active incident on record in the DEPLOY registry. 1 recall on record (1 serious). Most recent: Mar 2022. Retracted incidents are excluded from this count.

Fitbit trackers (now part of Google) track fitness metrics including steps, heart rate, sleep, and activity. Fitbit is becoming Google Health, with Google Pixel Watch incorporating Fitbit features. Fitbit has FDA-cleared ECG under 510(k) K200948 and AFib detection under K212372.